文献速递肾移植

混合免疫克服肾移植受者对新冠疫苗接种的免疫应答缺陷

Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2023-12-20

未感染KTR的疫苗应答显著低于HC,且与高龄、近期移植、移植肾再移植、动脉高血压及霉酚酸酯治疗相关;曾感染KTR的应答与HC相似,仅与移植至接种间隔相关。结论:混合免疫可克服免疫抑制,在KTR中提供有效的体液和细胞免疫。

要点

  • 未感染KTR对两剂BNT162b2的疫苗应答显著低于健康对照。
  • 高龄、近期移植、再移植、高血压及MMF治疗与未感染KTR低应答相关。
  • 曾感染SARS-CoV-2的KTR疫苗应答与健康对照相似,混合免疫可克服免疫抑制。

核心结论

  • 混合免疫可克服免疫抑制,在肾移植受者中提供有效的体液和细胞免疫。

研究设计与样本

  • 检测两剂BNT162b2 mRNA疫苗后的多功能抗体和T细胞应答,并用单变量和多变量分析关联临床特征。

主要发现

  • 未感染KTR的疫苗应答显著低于HC,且与高龄、近期移植、移植肾再移植、动脉高血压及MMF治疗相关。
  • 曾感染KTR的疫苗应答与HC相似,且仅与移植至接种间隔相关,与其他低应答风险因素无关。

临床怎么用

  • 对未感染KTR应关注高龄、近期移植、再移植、高血压及MMF治疗等低应答风险因素。
  • 曾感染SARS-CoV-2的KTR可能获得与健康对照相似的疫苗应答,混合免疫可提供保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Comorbidities and immunosuppressive therapies are associated with reduced immune responses to primary COVID-19 mRNA vaccination in kidney transplant recipients (KTRs). In healthy individuals, prior SARS-COV-2 infection is associated with increased vaccine responses, a phenotype called hybrid immunity. In this study, we explored the potential influence of immune suppression on hybrid immunity in KTRs. METHODS: Eighty-two KTRs, including 59 SARS-CoV-2-naïve (naïve KTRs [N-KTRs]) and 23 SARS-CoV-2-experienced (experienced KTRs [E-KTRs]) patients, were prospectively studied and compared to 106 healthy controls (HCs), including 40 SARS-CoV-2-naïve (N-HCs) and 66 SARS-CoV-2-experienced (E-HCs) subjects. Polyfunctional antibody and T cell responses were measured following 2 doses of BNT162b2 mRNA vaccine. Associations between vaccine responses and clinical characteristics were studied by univariate and multivariate analyses. RESULTS: In naïve KTRs, vaccine responses were markedly lower than in HCs and were correlated with older age, more recent transplantation, kidney retransplantation after graft failure, arterial hypertension, and treatment with mycophenolate mofetil (MMF). In contrast, vaccine responses of E-KTRs were similar to those of HCs and were associated with time between transplantation and vaccination, but not with the other risk factors associated with low vaccine responses in naïve KTRs. CONCLUSION: In conclusion, hybrid immunity overcomes immune suppression and provides potent humoral and cellular immunity to SARS-CoV-2 in KTRs.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gemander N, Kemlin D, Depickère S, et al. Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients. Kidney Int Rep. 2023. PMID: 38481503. doi:10.1016/j.ekir.2023.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。